excerpt BESPOKE-CRC protocol prespecifies adjuvant-treatment decisions as a primary endpoint: the study will observe how tumor-informed ctDNA testing changes clinicians' adjuvant chemotherapy choices (not a randomized de-escalation/escalation mandate like DYNAMIC). For the sub-topic, this anchor documents the observational spine's design intent—linking post-resection ctDNA dynamics to real-world adjuvant use and asymptomatic recurrence detection across stage I–IV CRC—while a secondary endpoint explicitly compares survival in MRD-negative patients who receive adjuvant chemotherapy versus active surveillance, which is the closest protocol-level analogue to the stage II de-escalation question (but not stage II–specific and not randomized). Population caveat remains: enrollment is stage I–IV and observational, so bearing on resected stage II colon cancer is inferential pending readout/supersede of interim abstracts.
nod_cc8f4dd3-6e2b-40a4-b1b5-537033bc98e7
Quoted span
The primary endpoints are to observe the impact of bespoke ctDNA testing on adjuvant treatment decisions and to measure CRC recurrence rates while asymptomatic and without imaging correlate.
Provenance
- Proposed by idn_f3a0c317-0b3f-4ef4-aac0-3217bbc9f5ad
- Created 2026-06-06T21:13:25.984Z
- Status: active